=>
Uploading C:\Program Files\Stnexp\Queries\10532633.str

chain nodes :
13 15 17
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-13 9-15 15-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-10 8-9 8-12 10-11 11-12
exact/norm bonds :
1-2 1-6 1-13 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-10 8-9 8-12 9-15 10-11 11-12 15-17

G1:C,S

G2:O,S

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 15:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,S
G2 O,S

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 12:05:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      194 TO ITERATE

100.0% PROCESSED      194 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          3045 TO     4715
PROJECTED ANSWERS:                1 TO       80

L2            1 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 12:06:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     4351 TO ITERATE

100.0% PROCESSED     4351 ITERATIONS                               18 ANSWERS
SEARCH TIME: 00.00.01

L3           18 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                        ENTRY     SESSION
FULL ESTIMATED COST                                    178.36     178.57

FILE 'CAPLUS' ENTERED AT 12:06:15 ON 15 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 15 Jun 2008 VOL 148 ISS 25
FILE LAST UPDATED: 13 Jun 2008 (20080613/ED)

=> s 13
L4 15 L3

=> d abs fbib hitstr 1-15

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
GI



I



II

AB The title compds. I [one of X1-X3 = S, and the other two represent C or N atoms; ring A = 6-10 membered aryl, 5-13 membered heteroaryl or partially aromatic heterocyclyl; R1 = H, halo, OH, CO2H, etc.; R2, R3 = H, alkyl, haloalkyl, etc.; n = 2-4; R4 = H, halo, S(alkyl), CN, etc.], that are useful for treating atherosclerosis, dyslipidemias and the like, were prepared and disclosed. E.g., a multi-step synthesis of II, starting from 3-(2-naphthyl)acrylic acid, was given. Compds. I generally have an IC50 in the 3H-nicotinic acid competition binding assay within the range of 1 nM to about 25 μM. Also compds. I generally have an EC50 in the functional in vitro GTPγS binding assay within the range of about less than 1 μM to as high as about 100 μM. Pharmaceutical compns. comprising the compound I alone or in combination with DP receptor antagonist, are also included.

AN 2007:1204726 CAPLUS Full-text
DN 147:486319

TI Preparation of N-(2-carboxythienyl) amides as niacin receptor agonists

IN Colletti, Steven L.; Tata, James R.; Chen, Weichun; Beresis, Richard T.; Ding, Fa-Xiang; Schmidt, Darby Rye; Shen, Hong; Raghavan, Subharekha
PA Merck & Co., Inc., USA

SO PCT Int. Appl., 58pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007120575	A2	20071025	WO 2007-US8584	20070406

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006-791019P P 20060411

OS MARPAT 147:486319

IT 688356-96-9 688357-16-6 688357-17-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-drug; preparation of N-(2-carboxythienyl) amides as niacin receptor agonists)

RN 688356-96-9 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-16-6 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-chlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-17-7 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-

7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = C or N; Z = (un)substituted aryl or heteroaryl; R1 independently = H, halo, CO2H, CN, etc.; R2 and R3 independently = H, alkyl, haloalkyl, alkoxy, etc.; R4 = H, F, or (un)substituted alkyl; R5 = CO2H, tetrazole, or CONHSO2R6 wherein R6 = (un)substituted alkyl or phenyl; m and p = 1 or 2 such that their sum = 3; n = 2-4; A = 6-10 membered], as well as their pharmaceutically acceptable salts are prepared and disclosed as useful for treating atherosclerosis, dyslipidemias and the like. Thus, e.g., II was prepared by conversion of 3-(4- bromophenyl)propionic acid to the amide with N-hydroxysuccinimide followed by reaction with triflate III to form the 4-bromophenylpropionamide derivative which was coupled with 4-hydroxyphenylboronic acid and hydrolyzed to give the desired product. In the 3H-nicotinic acid competition binding assay, I demonstrated IC50 values ranging from 1 nM to about 25 μM. Pharmaceutical compns. and methods of use are also included.

AN 2007:912171 CAPLUS Full-text

DN 147:277179

TI Preparation of carboxamidocyclohexenylcarboxylic acids derivatives as niacin receptor agonists, compositions containing such compounds and methods of treatment

IN Raghavan, Subharekha; Schmidt, Darby Rye; Colletti, Steven L.; Smenton, Abigail Lee

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 96pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007092364	A2	20070816	WO 2007-US2994	20070202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,				

TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
US 2006-765853P P 20060207

OS MARPAT 147:277179

IT 688357-16-6 688357-17-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed co-drugs for administration; preparation of cyclohexylcarboxylates as niacin receptor agonists)

RN 688357-16-6 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-chlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-17-7 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
GI



AB Title compds. [I; Q = (R1)3A[C(Ra)2]xCRb(NR2R3)(CHRc)y; A = aryl, heteroaryl; B = atoms to form Ph, thienyl, cyclohexenyl ring; R1 = H, halo, OH, CO2H, cyano, NH2, CORe, aminoalkyl, CONH2, (substituted) Ph, heteroaryl, etc.; Re = (substituted) alkyl, Ph; Ra, Rb, RC = H, alkyl, haloalkyl; R2, R3 = H, alkyl, haloalkyl; R4 = H, halo, (substituted) alkyl, aryl, heteroaryl, heterocyclyl, etc.; l of x, y = 0, the other = 1], were prepared Thus, N-(tert-butoxycarbonyl)-3-(2-naphthyl)-L-alanine in CH2Cl2 at -10° was treated with DCC, HOBT, and Et 2-aminobenzoate followed by stirring for 12-24 h to give a residue which was treated with KOH in THF/MeOH/H2O and then with CF3CO2H in CH2Cl2 to give title compound (II). I in the functional in vitro GTPγS binding assay showed EC50 values of about 1-100 μM.

AN 2007:728973 CAPLUS Full-text

DN 147:143658

TI Preparation of (hetero)aryl amino acid amides as niacin receptor agonists for treatment of atherosclerosis, dyslipidemia, diabetes, and metabolic syndrome.

IN Imbriglio, Jason; Colletti, Steven L.; Tata, James R.; Beresis, Richard T.; Marley, Daria; Raghavan, Subharekha; Schmidt, Darby Rye; Lins, Ashley Rouse; Smenton, Abigail L.; Chen, Weichun; Shen, Hong; Ding, Fa-Xiang; Bodner, Rena

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 78pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007075749	A2	20070705	WO 2006-US48535	20061220

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2005-751877P P 20051220

OS MARPAT 147:143658

IT 688356-96-9 688357-16-6 688357-17-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of (hetero)aryl amino acid amides as niacin receptor agonists for treatment of atherosclerosis, dyslipidemia, diabetes, and metabolic syndrome)

RN 688356-96-9 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-16-6 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-chlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-17-7 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
GI



I



II

AB Title compds. [I; 1-3 of W, X, Z = heteroatoms, the other = C; Y = C, N; 0-1 of W, X, Z = O, S, the remainder of W, X, Z = C, N; ring containing W, X, Y, Z is aromatic; A = 9-10 membered aryl, 8-10 membered heteroaryl, partially aromatic heterocyclyl; R1 = H, OH, halo, cyano, (substituted) alkyl, alkenyl, alkynyl, etc.; R2 = H, (substituted) alkyl, alkenyl; R3 = H, halo, Me, halomethyl; dotted lines = optional double bonds, either both present or both absent], were prepared Thus, title compound (II) was prepared from 4-bromo-3-methylthiophene-2-carboxylic acid, 6-hydroxy-2-naphthylboronic acid, and anthranilic acid. In a 3H-nicotinic acid competition binding assay, I showed IC50's of about 10 nM-25 μM.

AN 2007:351935 CAPLUS Full-text
DN 146:379811

TI Preparation of heterocyclylcarbonylaminobenzoic acids as niacin receptor agonists

IN Colletti, Steven L.; Imbriglio, Jason E.; Beresis, Richard Thomas; Frie, Jessica Leslie
PA Merck & Co., Inc., USA

SO PCT Int. Appl., 54pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007035478	A2	20070329	WO 2006-US36023	20060915
WO 2007035478	A3	20071122		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

			US 2005-718622P	P 20050920
AU 2006292559	A1	20070329	AU 2006-292559	20060915
			US 2005-718622P	P 20050920
			WO 2006-US36023	W 20060915

OS MARPAT 146:379811

IT 683356-96-9 683357-16-6 683357-17-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of heterocyclylcarbonylaminobenzoic acids as niacin receptor agonists)

RN 688356-96-9 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-16-6 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-chlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-17-7 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

GI



I



II

AB Title compds. I [wherein X = C or N; D = bond, O, CH2, CH2CH2 or CH2CH2CH2; B = (hetero)aryl; B' = H or absent; B and B' can be taken together to form a spiro ring while D = bond; Ra = H, halo, OH, etc.; Rb = H, halo, alkyl, etc.; Rc = COOH or tetrazol-5-yl; R4 = H, halo or (halo)methyl, with limitations] or pharmaceutically acceptable salts and solvates were prepared as niacin receptor agonists. Solid-phase synthesis of I such as II on Wang resin was disclosed. The invented compds. generally have EC50 in the range of 1 μM to 100 μM for niacin receptor in the binding assay. I are useful for the treatment of atherosclerosis, dyslipidemia, diabetes and other conditions.

AN 2007:259556 CAPLUS Full-text

DN 146:316951

TI Preparation of piperazinecarboxamides, diazepanecarboxamides and their analogs as niacin receptor agonists for the treatment of atherosclerosis, dyslipidemia and diabetes

IN Colletti, Steven L.; Shen, Hong; Tata, James R.; Szymonifka, Michael J.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 55pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007027532	A2	20070308	WO 2006-US33304	20060825
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
			US 2005-712275P	P 20050829
AU 2006285064	A1	20070308	AU 2006-285064	20060825
			US 2005-712275P	P 20050829
			WO 2006-US33304	W 20060825
CA 2620570	A1	20070308	CA 2006-2620570	20060825
			US 2005-712275P	P 20050829
			WO 2006-US33304	W 20060825

OS MARPAT 146:316951

IT 688356-96-9 688357-16-6 688357-17-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-drug; preparation of piperazinecarboxamides, diazepanecarboxamides and their analogs as niacin receptor agonists for treatment of atherosclerosis, dyslipidemia and diabetes)

RN 688356-96-9 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-16-6 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-chlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-17-7 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
GI



I



II

AB Title compds. I [X = CH2, O, S, etc.; a, b = 1-3 such as a + b = 2-4; ring A = aryl, heteroaryl, partially aromatic heterocyclic group, said heteroaryl and partially aromatic heterocyclic group containing at least one heteroatom selected from O, S, SO, etc., and optionally containing 1 other heteroatom selected from O and S, and optionally containing 1-3 addnl. N atoms, with up to 5 heteroatoms being present; R2, R3 = H, alkyl, haloalkyl, etc.; n = 1-5; R4 = H, halo, R6; R6 = alkyl optionally substituted with 1-3 groups, 0-3 of which are halo, and 0-1 of which are selected from the group consisting of O-alkyl, hydroxy, amino, etc.; R5 = -CO2H, tetrazol-5-yl, etc.; R1 = H, halo, hydroxy, etc.], pharmaceutically acceptable salts or solvates thereof were prepared For example, reaction of 3-(naphthalen-2-yl)propionic acid with methanesulfonyl chloride followed by in-situ treatment with Me 2-aminocyclohex-2-ene-1-carboxylate and hydrolysis using NaOH afforded compound II. The invented compds. generally have an IC50 in the 3H-nicotinic acid competition binding assays within the range of 1 nM to about 25 μM, and have an EC50 in the functional in vitro GTPγS binding assays within the range of about 1-100 μM.

AN 2006:1356948 CAPLUS Full-text

DN 146:100362

TI Preparation of 2-acylaminocycloalkenecarboxylic acids derivatives as niacin receptor agonists

IN Raghavan, Subharekha; Colletti, Steven L.; Ding, Fa-Xiang; Shen, Hong; Tata, James R.; Lins, Ashley Rouse; Smenton, Abigail Lee; Chen, Weichun; Schmidt, Darby Rye; Tria, George Scott

PA USA

SO U.S. Pat. Appl. Publ., 69pp.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 20060293364	A1	20061228	US 2006-474646		20060626
				US 2005-694711P	P	20050628
	AU 2006261839	A1	20070104	AU 2006-261839		20060626
				US 2005-694711P	P	20050628
				WO 2006-US24740	W	20060626
	CA 2611552	A1	20070104	CA 2006-2611552		20060626
				US 2005-694711P	P	20050628
				WO 2006-US24740	W	20060626
	WO 2007002557	A1	20070104	WO 2006-US24740		20060626

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

			US 2005-694711P	P	20050628
EP 1901731	A1	20080326	EP 2006-785553		20060626
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR					
			US 2005-694711P	P	20050628
			WO 2006-US24740	W	20060626
KR 2008019653	A	20080304	KR 2007-730918		20071228
			US 2005-694711P	P	20050628
			WO 2006-US24740	W	20060626

OS MARPAT 146:100362

IT 688356-96-9 688357-16-6 688357-17-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicaments with; preparation of 2-acylaminocycloalkenecarboxylic acids as niacin receptor agonists)

RN 688356-96-9 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-16-6 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-chlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-17-7 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-

7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
GI



AB Title compds. represented by the formula I [wherein R1 = (un)substituted cyclohexyl, Ph or heteroaryl; R2 = tetrazol-5-yl, 2,4-dioxo-oxazol-5-yl or CO2R; R = H or alkyl; n = 1 or 2; and pharmaceutically acceptable salts or solvates thereof] were prepared as Niacin receptor agonists. For example, II was provided in a multi-step synthesis starting from 3-ethoxy cyclopentenone. Certain I an IC50 in the niacin binding assay within the range of about 0.010-50 μM, and have an EC50 in the functional GTPγS binding assay within the range of about 0.010-100 1M. Thus, I and their pharmaceutical compns. are useful as Niacin receptor agonists for the treatment of dyslipidemias (no data).

AN 2006:1124674 CAPLUS Full-text
DN 145:455008
TI Preparation of pyrazole derivatives as Niacin receptor agonists
IN Imbriglio, Jason E.; Colletti, Steven L.; Tata, James R.; Liang, Rui; Raghavan, Subharekha; Schmidt, Darby R.; Smenton, Abigail R.; Chan, Sook Yee
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 83pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006113150	A1	20061026	WO 2006-US12876	20060407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,				

MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

				US 2005-670764P	P	20050413
AU 2006236939	A1	20061026		AU 2006-236939		20060407
				US 2005-670764P	P	20050413
				WO 2006-US12876	W	20060407
CA 2603757	A1	20061026		CA 2006-2603757		20060407
				US 2005-670764P	P	20050413
				WO 2006-US12876	W	20060407
EP 1874301	A1	20080109		EP 2006-740649		20060407
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR						
				US 2005-670764P	P	20050413
				WO 2006-US12876	W	20060407
IN 2007CN04216	A	20071221		IN 2007-CN4216		20070924
				US 2005-670764P	P	20050413
				WO 2006-US12876	W	20060407
CN 101160125	A	20080409		CN 2006-80012066		20071012
				US 2005-670764P	P	20050413
				WO 2006-US12876	W	20060407

OS MARPAT 145:455008

IT 688356-96-9P 688357-16-6P 688357-17-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazole derivs. as Niacin receptor agonists)

RN 688356-96-9 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-16-6 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-chlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-17-7 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



IT 688357-25-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole derivs. as Niacin receptor agonists)
RN 688357-25-7 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, ethyl ester (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
GI



I

AB A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP (prostaglandin D2) receptor antagonist. E.g, I was prepared by a series of reactions starting from 4-chloronicotinaldehyde. The compds. prepared function as selective DP antagonists and demonstrate an affinity for DP that is at least about 10 times higher than the affinity for CRTH2 receptors.

AN 2006:844718 CAPLUS Full-text

DN 145:271745

TI Preparation of pyridoindolizine and pyridoindole derivatives for treating atherosclerosis, dyslipidemias and related conditions

IN Fitzpatrick, Shaun; Seiler, Christian; Hardy, Ian; Waters, M., Gerard; Lai, Eseng

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 66pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006089309	A2	20060824	WO 2006-US6951	20060215
	WO 2006089309	A3	20070518		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
				US 2005-654703P	P 20050217
	AU 2006214018	A1	20060824	AU 2006-214018	20060215
				US 2005-654703P	P 20050217
				WO 2006-US6951	W 20060215
	CA 2598273	A1	20060824	CA 2006-2598273	20060215
				US 2005-654703P	P 20050217
				WO 2006-US6951	W 20060215
	EP 1855649	A2	20071121	EP 2006-721098	20060215
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

				US 2005-654703P	P	20050217
				WO 2006-US6951	W	20060215
US 20080139604	A1	20080612	US 2007-795484			20070718
				US 2005-654703P	P	20050217
				WO 2006-US6951	W	20060215
IN 2007CN03290	A	20071109	IN 2007-CN3290			20070726
				US 2005-654703P	P	20050217
				WO 2006-US6951	W	20060215
CN 101189011	A	20080528	CN 2006-80005127			20070816
				US 2005-654703P	P	20050217
				WO 2006-US6951	W	20060215

IT 887146-42-1P 887146-43-2P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridoindolizine and pyridoindole derivs for treating atherosclerosis, dyslipidemias and related conditions)

RN 887146-42-1 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, methyl ester, (8S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 887146-43-2 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, methyl ester, (8R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 688356-96-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyridoindolizine and pyridoindole derivs for treating atherosclerosis, dyslipidemias and related conditions)

RN 688356-96-9 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



IT 688357-16-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridoindolizine and pyridoindole derivs for treating atherosclerosis, dyslipidemias and related conditions)
RN 688357-16-6 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-chlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



IT 688357-25-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridoindolizine and pyridoindole derivs for treating atherosclerosis, dyslipidemias and related conditions)
RN 688357-25-7 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, ethyl ester (CA INDEX NAME)



L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

GI



I



II

AB The invention relates to certain fused pyrazole derivs. of formula I, and pharmaceutically acceptable salts thereof, which exhibit useful pharmacol. properties, for example, as agonists for the RUP25 receptor. Compds. of formula I wherein X is N, and Z is CR7, or X is CR7 and Z is N; one dotted lines are single and double bonds such that the ring containing X and Z is a pyrazole ring; R1 - R6 are independently H, C1-6 acyl(oxy), C2-6 alkenyl, C1-6 alkoxy, C1-6 alkyl(amino), C1-6 alkyl(thio)carboxamide, C2-6 alkynyl, etc.; R7 is carbo-C1-6 alkoxy, carboxy, or tetrazol-5-yl; and their pharmaceutically acceptable salts, hydrates, or solvates thereof are claimed. Also provided by the invention are pharmaceutical compns. containing compds. of the invention, and methods of using the compds. and compns. of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the invention also provides for the use of the compds. of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like. Example compound II was prepared by cyclization of (R)-2-(3-butenyl)oxirane; the resulting bicyclo[3.2.1]hexan-2-ol underwent oxidation of give bicyclo[3.2.1]hexane-2-one, which underwent cyclization with di-Et oxalate and hydrazine to give 1a,2,5,5a-tetrahydro-1H-2,3-diazacyclopropa[a]pentalene-4-carboxylic acid Et ester, which underwent amidation with ammonium hydroxide to give the corresponding amide, which benzylation with benzyl bromide followed by dehydration to give 2-benzyl-1a,2,5,5a-tetrahydro-1H-2,3-diazacyclopropa[a]pentalene-4- carbonitrile, which reacted with sodium azide to give 2-Benzyl-4-(2H- tetrazol-5-yl)-1a,2,5,5a-tetrahydro-2,3-diazacyclopropa[a]pentalene, which underwent debenzylation to give example compound II. All the invention compds. were evaluated for their antihyperglycemic activity, and 35S-GTPγS, human RUP25, and 3H-nicotinic acid receptor binding affinities. Certain compds. were determined to have an EC50 value in the cAMP whole cell method of about 25 μM or less. From the in vitro GTPγS binding assay, it was determined that tested compds. exhibited EC50 values in the range of about 1-100 μM, and the best compds. showed an EC50 value of less than about 1 μM. Certain tested compds. have an EC50 in the 3H-nicotinic acid binding competition assay, in the range of 1 to 100 μM , and the most favorable compds. exhibited an EC50 value of less than about 1 μM.

AN 2006:635044 CAPLUS Full-text

DN 145:103670

TI Fused pyrazole derivatives and their preparation, pharmaceutical compositions, and methods for treatment of metabolic-related disorders

IN Boatman, Douglas P.; Schrader, Thomas O.; Semple, Graeme; Skinner, Philip J.; Jung, Jae-Kyu

PA Arena Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 170 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006069242	A2	20060629	WO 2005-US46599	20051222
	WO 2006069242	A3	20060831		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
				US 2004-638668P	P 20041223
				US 2005-676521P	P 20050429
	AU 2005319121	A1	20060629	AU 2005-319121	20051222
				US 2004-638668P	P 20041223
				US 2005-676521P	P 20050429
				WO 2005-US46599	W 20051222
	CA 2589648	A1	20060629	CA 2005-2589648	20051222
				US 2004-638668P	P 20041223
				US 2005-676521P	P 20050429
				WO 2005-US46599	W 20051222
	US 20060205955	A1	20060914	US 2005-315753	20051222
	US 7241792	B2	20070710		
				US 2004-638668P	P 20041223
				US 2005-676521P	P 20050429
	EP 1831178	A2	20070912	EP 2005-857182	20051222
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
				US 2004-638668P	P 20041223
				US 2005-676521P	P 20050429
				WO 2005-US46599	W 20051222
	CN 101087765	A	20071212	CN 2005-80044454	20051222
				US 2004-638668P	P 20041223
				US 2005-676521P	P 20050429
				WO 2005-US46599	W 20051222
	US 20070073062	A1	20070329	US 2006-601184	20061117
				US 2004-638668P	P 20041223
				US 2005-676521P	P 20050429
				US 2005-315753	A1 20051222
	IN 2007KN02303	A	20070817	IN 2007-KN2303	20070621
				US 2004-638668P	P 20041223
				WO 2005-US46599	W 20051222
	NO 2007003766	A	20070921	NO 2007-3766	20070719

				US 2004-638668P	P 20041223
				US 2005-676521P	P 20050429
				WO 2005-US46599	W 20051222
KR 2007088808	A	20070829	KR 2007-716787		20070720
				US 2004-638668P	P 20041223
				US 2005-676521P	P 20050429
				WO 2005-US46599	W 20051222

OS MARPAT 145:103670

IT 688356-96-9P 688357-16-6P 688357-17-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of fused pyrazole derivs. and methods for treatment of metabolic-related disorders)

RN 688356-96-9 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-16-6 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-chlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-17-7 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
GI



AB The invention is related to biaryls I [Y = C, N; Z = C(RaRb)n; Ra, Rb = independently H, alkyl, OH, F, etc.; n = 1-5; R1 = CO2H, 1H-tetrazol-5-yl, CONHSO2Rc; Rc = (un)substituted alkyl, Ph; X10' = (X10)0-1; X1' = (X1)0-1' X1-X10 = C, or a heteroatom selected from O, S, and N, with provisos; each R2 = H, F, Cl, Br, I, alkyl, heterocyclyl, etc.; or two R2 groups taken together can form a fused Ph or fused heterocycle with ring B; each R3 = H, halo, halo/alkyl, halo/alkoxy, etc.; each R4 = H, halo, Me, etc.], as well as pharmaceutically acceptable salts, solvates, as niacin receptor agonists useful for treating atherosclerosis and dyslipidemias in combination with DP antagonists. The invention is also related to the preparation of DP antagonists. Pharmaceutical compns. comprising I are also included. Thus, anthranilide II was prepared by Pd-coupling of 3-(4-iodophenyl)propionic acid with phenylboronic acid, chlorination of biaryl propionic acid (no data) with SOCl2, and amidation of acyl chloride (no data) with anthranilic acid. I have an EC50 in the functional assay in vitro GTPγS binding assay within the range of about less than 1 μM to as high as about 100 μM. Have an IC50 in the 3H-nicotinic acid competition binding assay within the range of 1 nM to about 25 μM. Selected I do not exhibit measurable in vivo vasodilation in the murine flushing model at doses up to 100 mg/kg or 300 mg/kg in the presence of DP antagonists.

AN 2006:513667 CAPLUS Full-text

DN 145:27731

TI Preparation of biaryl compounds, particularly N-(biarylpropionyl)anthranilides, as niacin receptor agonists and pyridoindolizine derivatives as DP receptor antagonists, their pharmaceutical compositions and their combination useful for treating atherosclerosis and dyslipidemias

IN Colletti, Steven L.; Tata, James R.; Shen, Hong C.; Ding, Fa-Xiang; Frie, Jessica L.; Imbriglio, Jason E.; Chen, Weichun

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 100 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2006057922	A2	20060601	WO 2005-US41962		20051118
	WO 2006057922	A3	20060831			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
				US 2004-630281P	P	20041123
	AU 2005309737	A1	20060601	AU 2005-309737		20051118
				US 2004-630281P	P	20041123
				WO 2005-US41962	W	20051118
	CA 2587207	A1	20060601	CA 2005-2587207		20051118
				US 2004-630281P	P	20041123
				WO 2005-US41962	W	20051118
	EP 1824812	A2	20070829	EP 2005-824876		20051118
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
				US 2004-630281P	P	20041123
				WO 2005-US41962	W	20051118
	CN 101061092	A	20071024	CN 2005-80039913		20051118
				US 2004-630281P	P	20041123
				WO 2005-US41962	W	20051118
	IN 2007CN01774	A	20070831	IN 2007-CN1774		20070430
				US 2004-630281P	P	20041123
				WO 2005-US41962	W	20051118
	US 20070281969	A1	20071206	US 2007-791183		20070517
				US 2004-630281P	P	20041123
				WO 2005-US41962	W	20051118

OS MARPAT 145:27731

IT 688356-96-9P 688357-16-6P 688357-17-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(DP receptor antagonist; preparation of biaryl compds. as niacin receptor agonists and pyridoindolizine derivs. as DP receptor antagonists and their combination useful for treating atherosclerosis and dyslipidemias)

RN 688356-96-9 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-16-6 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-chlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-17-7 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



IT 688357-27-9P 688357-28-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of biaryl compds. as niacin receptor agonists and pyridoindolizine derivs. as DP receptor antagonists and their combination useful for treating atherosclerosis and dyslipidemias)
RN 688357-27-9 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, methyl ester, (+)- (CA INDEX NAME)

Rotation (+).



RN 688357-28-0 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, methyl ester, (-)- (CA INDEX NAME)

Rotation (-).



L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
GI



I

AB A method of treating pathol. blushing is disclosed wherein the patient is administered a DP (prostaglandin D2) receptor antagonist. E.g, I was prepared by a series of reactions starting from 4-chloronicotinaldehyde. The compds. prepared function as selective DP antagonists and demonstrate an affinity for DP that is at least about 10 times higher than the affinity for CRTH2 receptors.
AN 2006:471897 CAPLUS Full-text

DN 144:488635
TI Preparation of compounds such as pyridoindolizine and indole derivatives as prostaglandin D2 antagonists for treating pathological blushing
IN Tobert, Jonathan A.; Lai, Eseng
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006052798	A2	20060518	WO 2005-US40117	20051107
WO 2006052798	A3	20070111		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

			US 2004-625823P	P 20041108
US 20070299122	A1	20071227	US 2007-667346	20070508
			US 2004-625823P	P 20041108
			WO 2005-US40117	W 20051107

OS CASREACT 144:488635
IT 688356-96-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of compds. such as pyridoindolizine and indole derivs. as prostaglandin D2 antagonists for treating pathol. blushing)
RN 688356-96-9 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



IT 688357-16-6P 688357-17-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of compds. such as pyridoindolizine and indole derivs. as prostaglandin D2 antagonists for treating pathol. blushing)

RN 688357-16-6 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-chlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-17-7 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



IT 688357-25-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of compds. such as pyridoindolizine and indole derivs. as prostaglandin D2 antagonists for treating pathol. blushing)
RN 688357-25-7 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, ethyl ester (CA INDEX NAME)



IT 887146-42-1P 887146-43-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of compds. such as pyridoindolizine and indole derivs. as prostaglandin D2 antagonists for treating pathol. blushing)

RN 887146-42-1 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, methyl ester, (8S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 887146-43-2 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, methyl ester, (8R)- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
GI



I



II

AB The invention relates to niacin receptor agonists of formula I; as well as pharmaceutically acceptable salts and solvates. The compds. are useful for treating dyslipidemias, and in particular, reducing serum LDL, VLDL and triglycerides, and raising HDL levels. Pharmaceutical comps. and methods of treatment are also included. Compds. of formula I wherein Y is C or N; R1 and R2 are independently H, (halo)C1-3 alkyl(oxy), OC1-3 alkyl, OH, or F; R3 is Co2H, tetrazolyl, or CONHSO2H and derivs.; R4 is H, halo, or (halo)methyl; B is (un)substituted 10-membered bicyclic aryl, (un)substituted 9- to 10-membered bicyclic heteroaryl, or (un)substituted 12- to 13-membered tricyclic heteroaryl; n is an integer from 1 to 4, such that when (CR1R2)n represent CH(Me)CH2, the ring B is (un)substituted bicyclic aryl; and their pharmaceutically acceptable salts and solvates thereof. Example compound II was prepared by amidation of 3-(1-naphthyl)acrylic acid with Me anthranilate followed by catalytic hydrogenation. All the invention compds. were tested for their niacin receptor affinity. From the assay, it was determined that most of the compds. in general exhibited in vitro EC50 values in the range of about 1 μM to as high as about 100 μM.

AN 2006:469551 CAPLUS Full-text

DN 144:488409

TI N-Acyl anthranilic acid and related compounds as niacin receptor agonists, and their preparation, pharmaceutical compositions and methods of treatment of dyslipidemias

IN Colletti, Steven L.; Beresis, Richard T.; Chen, Weichun; Tata, James R.; Shen, Hong C.; Marley, Daria M.; Deng, Qiaolin; Frie, Jessica L.; Ding, Fa-Xiang

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006052555	A2	20060518	WO 2005-US39523	20051030
	WO 2006052555	A3	20060622		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
				US 2004-624816P	P 20041104
	AU 2005305072	A1	20060518	AU 2005-305072	20051030
				US 2004-624816P	P 20041104
				WO 2005-US39523	W 20051030
	CA 2586156	A1	20060518	CA 2005-2586156	20051030
				US 2004-624816P	P 20041104
				WO 2005-US39523	W 20051030
	EP 1809284	A2	20070725	EP 2005-825014	20051030
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
				US 2004-624816P	P 20041104
				WO 2005-US39523	W 20051030
	CN 101056635	A	20071017	CN 2005-80038027	20051030

				US 2004-624816P	P	20041104
				WO 2005-US39523	W	20051030
JP 2008518957	T	20080605	JP 2007-539301			20051030
			US 2004-624816P	P	20041104
			WO 2005-US39523	W	20051030
IN 2007CN01653	A	20070831	IN 2007-CN1653			20070423
			US 2004-624816P	P	20041104
			WO 2005-US39523	W	20051030
US 20070299101	A1	20071227	US 2007-666966			20070502
			US 2004-624816P	P	20041104
			WO 2005-US39523	W	20051030

OS MARPAT 144:488409

IT 688357-17-7P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(drug candidate; preparation of N-acyl anthranilic acid and related compds. as niacin receptor agonists and their methods of treatment of dyslipidemias)

RN 688357-17-7 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



IT 887401-58-3P 887401-59-4P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of N-acyl anthranilic acid and related compds. as niacin receptor agonists and their methods of treatment of dyslipidemias)

RN 887401-58-3 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, (+)- (CA INDEX NAME)

Rotation (+).



RN 887401-59-4 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, (-)- (CA INDEX NAME)

Rotation (-).



IT 688356-96-9P 688357-16-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N-acyl anthranilic acid and related compds. as niacin receptor agonists and their methods of treatment of dyslipidemias)
RN 688356-96-9 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-16-6 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-chlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
GI



I



II

AB The invention is related to a method of treating atherosclerosis, dyslipidemia and related conditions wherein a nicotinic acid receptor partial/agonist I, or one of its pharmaceutically acceptable salts or solvates, is administered to a human patient in combination with a DP receptor antagonist, e.g. II, in amts. that are effective for treatment in the absence of substantial flushing. The invention is also related to the preparation of tetrazole I and DP antagonists. Thus, I was prepared by reaction of cyclopentanone with diethylmalonate (no data for the intermediate), followed by cyclization with hydrazine hydrochloride, amidation of the ester with methanolic ammonia, dehydration of the amide, and cyclization of the nitrile with NaN3. An 11-step synthesis was given for pyridoindolizine II (no data for the intermediates). II, and its derivs., having a binding affinity (Ki) for CRTH2 of about ≥ 0.5 μM, and a selectivity for the DP receptor over CRTH2 of at least about 10 fold, are useful to inhibit the flushing effect seen when tetrazole I or its pharmaceutically acceptable salts or solvates are administered alone.

AN 2006:212213 CAPLUS Full-text
DN 144:292761

TI Preparation of 3-(2H-tetrazol-5-yl)-1,4,5,6-tetrahydrocyclopentapyrazole as nicotinic agonist and pyridoindolizine derivatives as DP receptor antagonists , and their combination useful for treating atherosclerosis, dyslipidemias and related conditions

IN Waters, M. Gerard; Turner, Mervyn
PA Merck & Co., Inc., USA

SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2006026273	A2	20060309	WO 2005-US30001	20050824
	WO 2006026273	A3	20060908		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

				US 2004-604443P	P 20040825
	US 20070244107	A1	20071018	US 2007-631741	20070105
				US 2004-604443P	P 20040825
				WO 2005-US30001	W 20050824

OS CASREACT 144:292761

IT 688356-96-9P 688357-16-6P 688357-17-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(DP receptor antagonist; preparation of a nicotinic agonist and DP receptor antagonists, and their combination useful for treating atherosclerosis, dyslipidemias and related conditions)

RN 688356-96-9 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-16-6 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-chlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-17-7 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



IT 688357-27-9P 688357-28-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of a nicotinic agonist and DP receptor antagonists, and their combination useful for treating atherosclerosis, dyslipidemias and related conditions)

RN 688357-27-9 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, methyl ester, (+)- (CA INDEX NAME)

Rotation (+).



RN 688357-28-0 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, methyl ester, (-)- (CA INDEX NAME)

Rotation (-).



L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AB A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.

AN 2004:999670 CAPLUS Full-text
DN 141:420447

TI Method of treating atherosclerosis, dyslipidemias and related conditions

IN Cheng, Kang; Waters, M. Gerard; Metters, Kathleen M.; O'Neill, Gary
PA USA

SO U.S. Pat. Appl. Publ., 33 pp.
CODEN: USXXCO
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040229844	A1	20041118	US 2004-844773	20040513
				US 2003-470665P P	20030515
	AU 2004240597	A1	20041202	AU 2004-240597	20040513
				US 2003-470665P P	20030515
				WO 2004-US14980 W	20040513
	CA 2525772	A1	20041202	CA 2004-2525772	20040513
				US 2003-470665P P	20030515
				WO 2004-US14980 W	20040513
	WO 2004103370	A1	20041202	WO 2004-US14980	20040513
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2003-470665P P	20030515
	EP 1624871	A1	20060215	EP 2004-785539	20040513
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
				US 2003-470665P P	20030515
				WO 2004-US14980 W	20040513
	BR 2004010273	A	20060516	BR 2004-10273	20040513
				US 2003-470665P P	20030515
				WO 2004-US14980 W	20040513
	CN 1787819	A	20060614	CN 2004-80012853	20040513
				US 2003-470665P P	20030515
	JP 2006526030	T	20061116	JP 2006-515355	20040513
				US 2003-470665P P	20030515
				WO 2004-US14980 W	20040513
	IN 2005DN04759	A	20071207	IN 2005-DN4759	20051019
				US 2003-470665P P	20030515
				WO 2004-US14980 W	20040513
	MX 2005PA12272	A	20060519	MX 2005-PA12272	20051114
				US 2003-470665P P	20030515
				WO 2004-US14980 W	20040513
	KR 806008	B1	20080226	KR 2005-721795	20051115
				US 2003-470665P P	20030515

				WO 2004-US14980	W	20040513
NO 2005005957	A	20060214		NO 2005-5957		20051214
				US 2003-470665P	P	20030515
				WO 2004-US14980	W	20040513
KR 2008003470	A	20080107		KR 2007-729888		20071221
				US 2003-470665P	P	20030515
				WO 2004-US14980	W	20040513
				KR 2005-721795	A3	20051115

IT 688356-96-9P 688357-16-6P 688357-17-7P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(method of treating atherosclerosis, dyslipidemias and related conditions)

RN 688356-96-9 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-16-6 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-chlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-17-7 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



IT 688357-25-7P 794535-39-0P 794535-46-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(method of treating atherosclerosis, dyslipidemias and related conditions)
RN 688357-25-7 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, ethyl ester (CA INDEX NAME)



RN 794535-39-0 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, (8R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 794535-46-9 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein G = O(CH2)1-2, S(CH2)1-2, (un)substituted C1-3alkyl; Ar = hetero/aryl optionally substituted with Rg; Q = CO2H, CONH2 and derivs., SO2NH2 and derivs., SO3H, PO3H2 and tetrazolyl; one of A, B, C, or D is N and the others are independently selected from CH and CRg; E = (CH2)a-X-(CH2)b, phenylene, cycloalkylidene, cycloalkylene, etc.; a, b = 0-1, X = a bond, O, S, NH and derivs., etc.; F = (CH2)m and derivs., CH:CH and derivs.; m = 1-3; R1 = H, CN, OH and derivs., (un)substituted alkyl, etc.; R2 = H, alkyl optionally substituted with 1-6 halogens; R1R2 = oxo; or R1R2 = (un)substituted 3- or 4-membered ring, optionally containing 1 heteroatom; R3 = H, (un)substituted alkyl; Rg = halo, CN, CHO, CO2H and derivs., CONH2 and derivs., NH2 and derivs., NO2, alkoxy, OCONH2 and derivs., SO2-alkyl, (un)substituted alk/en/yl, etc.] were prepared as prostaglandin receptor, in particular PGD2, antagonists useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion and asthma (no data). Six biol. assays are given (no data). Thus, reaction of II (preparation given) with a mixture of bis(3,4-dichlorophenyl)disulfide, SO2Cl2, 1,2-dichloroethane, followed by hydrolysis gave the pyridoindolizinyl acid III.

AN 2004:390250 CAPLUS Full-text
DN 140:406734
TI Preparation of pyridopyrrolizines and pyridoindolizines as prostaglandin receptor, in particular PGD2, antagonists
IN Leblanc, Yves; Dufresne, Claude; Roy, Patrick
PA Merck Frosst Canada & Co., Can.
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004039807	A1	20040513	WO 2003-CA1658	20031028
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2002-422443P	P	20021030
				US 2003-482626P	P	20030626
CA 2503767	A1	20040513	CA 2003-2503767			20031028
			US 2002-422443P	P		20021030
			US 2003-482626P	P		20030626
			WO 2003-CA1658	W		20031028
AU 2003275868	A1	20040525	AU 2003-275868			20031028
			US 2002-422443P	P		20021030
			US 2003-482626P	P		20030626
			WO 2003-CA1658	W		20031028
EP 1558614	A1	20050803	EP 2003-809672			20031028

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

				US 2002-422443P	P	20021030
				US 2003-482626P	P	20030626
				WO 2003-CA1658	W	20031028
BR 2003015681	A	20050906	BR 2003-15681			20031028
			US 2002-422443P	P		20021030
			US 2003-482626P	P		20030626
			WO 2003-CA1658	W		20031028
CN 1732171	A	20060208	CN 2003-80107732			20031028
			US 2002-422443P	P		20021030
			US 2003-482626P	P		20030626
JP 2006506457	T	20060223	JP 2005-501791			20031028
			US 2002-422443P	P		20021030
			US 2003-482626P	P		20030626
			WO 2003-CA1658	W		20031028
NZ 539406	A	20070531	NZ 2003-539406			20031028
			US 2002-422443P	P		20021030
			US 2003-482626P	P		20030626
			WO 2003-CA1658	W		20031028
US 20050272756	A1	20051208	US 2005-532633			20050425
			US 2002-422443P	P		20021030
			US 2003-482626P	P		20030626
			WO 2003-CA1658	W		20031028
MX 2005PA04715	A	20050803	MX 2005-PA4715			20050429
			US 2002-422443P	P		20021030
			US 2003-482626P	P		20030626
			WO 2003-CA1658	W		20031028
NO 2005002591	A	20050729	NO 2005-2591			20050527
			US 2002-422443P	P		20021030
			US 2003-482626P	P		20030626
			WO 2003-CA1658	W		20031028

OS MARPAT 140:406734

IT 688357-25-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyridopyrrolizines and pyridoindolizines as prostaglandin D2 receptor antagonists)

RN 688357-25-7 CAPLUS

CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, ethyl ester (CA INDEX NAME)



IT 688357-17-7P 688357-27-9P 688357-28-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prostaglandin D2 receptor antagonist; preparation of pyridopyrrolizines and pyridoindolizines as prostaglandin D2 receptor antagonists)

RN 688357-17-7 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



RN 688357-27-9 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, methyl ester, (+)- (CA INDEX NAME)

Rotation (+).



RN 688357-28-0 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)-, methyl ester, (-)- (CA INDEX NAME)

Rotation (-).



IT 688356-96-9P 688357-16-6P 688357-46-2P
688357-48-4P 688357-49-5P 688357-50-8P
688357-51-9P 688357-69-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prostaglandin D2 receptor antagonist; preparation of pyridopyrrolizines and pyridoindolizines as prostaglandin D2 receptor antagonists)

RN 688356-96-9 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(3,4-dichlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-16-6 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-chlorophenyl)thio]-7,8-dihydro-1-(methylsulfonyl)- (CA INDEX NAME)



RN 688357-46-2 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-fluorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



RN 688357-48-4 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-chlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



RN 688357-49-5 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(2,4-dichlorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



RN 688357-50-8 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-bromophenyl)thio]-7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



RN 688357-51-9 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(2-chloro-4-fluorophenyl)thio]-7,8-dihydro-1-(1-methylethyl)- (CA INDEX NAME)



RN 688357-69-9 CAPLUS
CN 6H-Pyrido[3,4-b]pyrrolizine-8-acetic acid, 9-[(4-chlorophenyl)thio]-7,8-dihydro-1-(1-methoxypropyl)- (CA INDEX NAME)